News and Announcements
First Graphene Ltd (ASX: FGR) Raises $3.2 Million by Share Placement
- Published March 19, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- FGR has successfully raised $3.2 million in the most recent share placement.
- These funds will be used to increase international awareness as FGR was approached by a European-based industrialist wanting to introduce graphene to its products.
Advanced materials company, First Graphene Limited (ASX: FGR) is pleased to advise it has received firm commitments for a placement of shares at $0.18 raising $3.2 million.
The international awareness strategy of First Graphene is gaining traction. This strategy is based on enhancing the international awareness of the company’s leading position as a high-quality supplier of bulk volume graphene as well as a creator of valuable IP.
FGR recently participated in a technology-based conference held in Singapore, where it received a conducive reception. This was mainly influenced by Singapore’s active involvement in the search for technology and advanced sciences. FGR is more likely to expand its business in Singapore as a result of the country’s connections with the Asian countries as well as businesses.
The company has raised $3.2 million following the acquisition of firm commitments for the placement of shares at $0.18. Shareholder approval will not be needed for the 17.7m shares issue as well as the option securities issue. The FGROC options are set to be attached by the shares issued on a ratio of 1:2. Most of the shares in the placement will go to a European-based
industrialist. A detailed study of the companies with graphene credentials as well as the graphene sector saw the industrialist approach FGR. This exhibited FGR as a company of merit hence boosting its reputation.
About First Graphene Limited (ASX: FGR)
First Graphene is an advanced materials company seeking to position itself in the lowest cost quartile of global graphene suppliers. It has developed an environmentally sound and safe method of converting its supplies of ultra-high-grade graphite into the lowest cost highest quality graphene, in bulk quantities.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
